14 Aug 2017 10:00
14 August 2017
Diurnal Group plc
("Diurnal" or the "Company")
Notice of Final Results
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will announce its financial results for the year ended 30 June 2017 on Wednesday, 6 September 2017.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, CEO | |
Richard Bungay, CFO | |
Numis Securities Ltd (Nominated Adviser and Joint Broker) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Freddie Barnfield, Paul Gillam | |
Corporate Broking: James Black | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley / Duncan Monteith | |
Corporate Broking: Tom Salvesen | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
DNL.L (DNL)